Sympathetic hyperactivity - A hidden enemy in chronic kidney disease patients

Peritoneal Dialysis International

Volumn 27, Issue SUPPL. 2, 2007, Pages

  Blankestijn, Peter J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Angiotensin II; Chronic kidney disease; Renal hypertension; Sympathetic activity

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPROSARTAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; MOXONIDINE; NEBIVOLOL;

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL PROTOCOL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONGESTIVE CARDIOMYOPATHY; DISEASE MODEL; DRUG EFFICACY; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; KIDNEY INJURY; MONOTHERAPY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SYMPATHETIC TONE;

ANIMALS; HUMANS; HYPERTENSION, RENAL; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; SYMPATHETIC NERVOUS SYSTEM;

EID: 35748940656     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (46)

1. Blankestijn PJ. Sympathetic hyperactivity in chronic kidney disease. Nephrol Dial Transplant 2004; 19:1354-7.
2. Joles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension 2004; 43:699-706.
3. Koomans HA, Blankestijn PJ, Joles JA. Sympathetic hyperactivity in chronic renal failure: a wake-up call. J Am Soc Nephrol 2004; 15:524-37.
4. Neumann J, Ligtenberg G, Klein II, Koomans HA, Blankestijn PJ. Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. Kidney Int 2004; 65:1568-76.
5. Blankestijn PJ, Ligtenberg G. Volume-independent mechanisms of hypertension in hemodialysis patients: clinical implications. Semin Dial 2004; 17:265-9.
6. Augustyniak RA, Tuncel M, Zhang W, Toto RD, Victor RG. Sympathetic overactivity as a cause of hypertension in chronic renal failure. J Hypertens 2002; 20:3-9.
7. Campese VM, Mitra N, Sandee D. Hypertension in renal parenchymal disease: why is it so resistant to treatment? Kidney Int 2006; 69:967-73.
8. Kotanko P. Cause and consequences of sympathetic hyperactivity in chronic kidney disease. Blood Purif 2006; 24:95-9.
9. Grassi G, Esler M. How to assess sympathetic activity in humans. J Hypertens 1999; 17:719-34.
10. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327: 1912-18.
11. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002; 106:1974-9.
12. Klein IH, Ligtenberg G, Neumann J, Oey PL, Koomans HA, Blankestijn PO. Sympathetic nerve activity is inappropriately increased in chronic renal disease. J Am Soc Nephrol 2003; 14:3239-44.
13. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension, J Am Soc Nephrol 2001; 12:2427-33.
14. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol 2003; 14:425-30.
15. Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, Dijkhorst-Oei LT, Boomsma F, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999; 340:1321-8.
16. Neumann J, Ligtenberg G, Oey L, Koomans HA, Blankestijn PJ. Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure. J Am Soc Nephrol 2004; 15:2902-7.
17. Tinucci T, Abrahao SB, Santello JL, Mion D Jr. Mild chronic renal insufficiency induces sympathetic overactivity. J Hum Hypertens 2001; 15:401-6.
18. Miyajima E, Yamada Y, Yoshida Y, Matsukawa T, Shionoiri H, Tochikubo O, et al. Muscle sympathetic nerve activity in renovascular hypertension and primary aldosteronism. Hypertension 1991; 17:1057-62.
19. Kielstein JT, Impraim B, Simmel S. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004; 109:172-7.
20. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study, Lancet 2001; 358: 2113-17.
21. Zoccali C, Mallamaci F, Maas R, Benedetto FA, Tripepi G, Malatino LS, et al. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 2002; 62:339-45.
22. Mallamaci F, Zoccali C, Messineo L, Partongo S, Postorino M. The influence of volume depletion and central hypovolemia on the plasma concentration of parathyroid hormone in dialysis patients. J Am Soc Nephrol 1997; 8:1574-8.
23. Hanly PJ, Pierratos A. Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis. N Engl J Med 2001; 344:102-7.
24. Schohn D, Weidmann P, Jahn H, Beretta-Piccoli C. Norepinephrine-related mechanism in hypertension accompanying renal failure. Kidney Int 1985; 28:814-22.
25. Greenwood JP, Scott EM, Stoker JB, Mary DA. Hypertensive left ventricular hypertrophy: relation to peripheral sympathetic drive. J Am Coll Cardiol 2001; 38:1711-17.
26. Kelm M, Schafer S, Mingers S, Heydthausen M, Vogt M, Motz W, et al. Left ventricular mass is linked to cardiac noradrenaline in normotensive and hypertensive patients. J Hypertens 1996; 14:1357-64.
27. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003; 108:560-5.
28. Zoccali C, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Benedetto FA, et al. Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension 2002; 40:41-6.
29. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Cataliotti A, et al. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 2001; 12:2768-74.
30. Mancia G, Grassi G, Giannattasio C, Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 1999; 34:724-8.
31. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105:1354-9.
32. Amann K, Koch A, Hofstetter J, Gross ML, Haas C, Orth SR, et al. Glomerulosclerosis and progression: effect of subantihypertensive doses of alpha and beta blockers. Kidney Int 2001; 60:1309-23.
33. Amann K, Rump LC, Simonaviciene A, Oberhauser V, Wessels S, Orth SR, et al. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol 2000; 11:1469-78.
34. Strojek K, Grzeszczak W, Gorska J, Leschinger MI, Ritz E. Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy? J Am Soc Nephrol 2001; 12:602-5.
35. Cice G, Ferrara L, D'Andrea A, D'Isa S, Di Benedetto A, Cittadini A, et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 2003; 41:1438-44.
36. Cice G, DiBenedetto A, D'Isa S, D'Andrea A, DeGregorio P, Calabro R. Effect of telmisartan added to ACE inhibitors in reducing morbidity and mortality in hemodialysis patients with chronic heart failure (Abstract). J Hypertens 2006; 24(Suppl 4):S21.
37. Chan CT, Harvey PJ, Picton P, Pierratos A, Miller JA, Floras JS. Short-term blood pressure, noradrenergic and vascular effects of nocturnal home hemodialysis. Hypertension 2003; 42:925-31.
38. Zilch O, Vos PF, Oey PL, et al. Sympathetic hyperactivity in hemodialysis patients is reduced by short daily hemodialysis. J Hypertens 2007; [In press].
39. Kielstein JT, Bode-Boger SM, Frotich JC, Halter H, Boger RH. Relationship of asymmetric dimethylarginine to dialysis treatment and atherosclerotic disease. Kidney Int 2001; 59(Suppl 78):S9-13.
40. Zoccali C. Traditional and emerging cardiovascular and renal risk factors: an epidemiologic perspective. Kidney Int 2006; 70:26-33.
41. Nishiyama A, Seth DM, Navar LG. Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats. Hypertension 2002; 39:129-34.
42. Song JH, Cha SH, Hong SB, Kim DH. Dual blockade of the renin-angiotensin system with angiotensin converting-enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease. J Hypertens 2006; 24(Suppl 1): S101-6.
43. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor btockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005; 67:799-812.
44. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controtted trial. Lancet 2003; 361:117-24.
45. Penne EL, Neumann J, Klein IH, Koomans HA, Blankestijn PJ. Relation between sympathetic hyperactivity and clinical outcome in chronic kidney disease patients (Abstract). J Hypertens 2006; 24(Suppl 4):S294.
46. Sinski M, Lewandowski J, Bidiuk J, Abramczyk P, Gaciong Z. Atorvastatin reduces sympathetic activity in patients with essential hypertension and hypercholesteremia (Abstract). J Hypertens 2006; 24(Suppl 4):SJ81.